RE: RE: RE: RE: RE: I hope...... agreed... though this financing seemingly came out of the blue, at the end of the day, on the Venture market, cash is always king and we will now surely have enough to get through the end of the trial..
though tomorrow will prove to be interesting, I do see it as an opportunity for all us retail folks to average down.
I left a message for management and their CFO was kind enough to call me back and we talked at great length and I am now convinced that this financing, though hard to swallow dilution wise, is going to serve all of us... Keep in mind, both the CEO and CFO both own in excess of 3% of the stock each, so they naturally wouldnt do this unless it was in everyones best interest.
JD, though I thoroughly enjoy your insights to date, one aspect of your last post is actually inaccurate. Though a potential licensing deal is likely not going to happen in the next month or two, that shouldnt be a reason to sell at this point as the Company has already announced, and it was reaffirmed in my conversation today, that Interim Phase 2 data will be released shortly.
With cash on hand to clearly get us through the end of the trial, and more results to be released in the coming weeks(with the potential for efficacy), ICO will be almost completely de-risked in the eyes of the market. Also, as is typical for Phase 2 trials nearing completion, they tend to go on a massive spec run at right around the junction we now find ourself(about 3/4s of the way through trial).
Cash on hand; impending results and the potential for what is a typical spec run seen in Companys at this stage give plenty of reason to hold and/or average down at this point.